FIGURE 7.

Fyn kinase inhibition prevents activation of Pyk2 but does not alter activation of CamKII. A, representative immunoblots showing Pyk2 (Tyr-402) and CamKII (Thr-286) phosphorylation states after treatment of acute brain slices. Slices were pretreated with 2 μm AZD0530 for 2 h prior to exposure to DHPG (15 min), Aβo (30 min), or DHPG+Aβo (15 min of Aβo pretreatment followed by 15-min DHPG treatment). DMSO was used as vehicle, and the DMSO content was constant in all lanes. B and C, densitometric analysis of the immunoblots from A. Data are mean ± S.E. In the absence of AZD0530, n = 11 independent experiments for vehicle or DHPG treatment, n = 21 independent experiments for Aβo treatment, and n = 8 independent experiments for DHPG+Aβo treatment. In the presence of AZD0530, n = 2 independent experiments for vehicle, DHPG, or DHPG+Aβo treatment, and n = 3 independent experiments for Aβo treatment. 3 slices/treatment condition and experiment were averaged. B, Pyk2 phosphorylation at Tyr-402 is enhanced by all treatment conditions (*, p < 0.05 by two-way ANOVA with post-hoc Tukey's multiple comparisons test). AZD0530 pretreatment slightly suppresses basal p-Pyk2 (Tyr-402) levels and prevents DHPG/Aβo-induced activation of Pyk2 (ns, p > 0.05). C, CamKII phosphorylation at Thr-286 is enhanced by all treatment conditions in the absence and presence of AZD0530 (***, p < 0.001; *, p < 0.05; by two-way ANOVA with Fisher's LSD post hoc pairwise comparisons test).